Ancell

anti-CD133 (human), mAb (ANC9C5) (R-PE)

CHF 455.00
In stock
ANC-363-050120 testsCHF 455.00
More Information
Product Details
Synonyms Prominin-1; PROM1; AC133; Prominin-like Protein 1
Product Type Monoclonal Antibody
Properties
Clone ANC9C5
Isotype Mouse IgG1κ
Source/Host Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen WERI-Rb-1 human retinoblastoma cells.
Label/Conjugates R-PE
Application

Flow Cytometry

Crossreactivity Human
Specificity

Recognizes epitope 1 of human CD133.

Purity ≥95% (SDS-PAGE)
Purity Detail Protein A purified.
Concentration 300μg/ml
Formulation Liquid, 50 mM Sodium Phosphate pH 7.5, 500 mM Potassium Chloride, 150mM NaCl, 15% Glycerol, 0.2% BSA, 0.04% Sodium Azide.
Isotype Negative Control

Mouse IgG1 Isotype Control (R-PE)

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by Ancell Corporation.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Do not freeze.
Protect from light.
Use/Stability Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Human CD133 is a 117kd pentaspan transmembrane glycoprotein expressed by a subset of hematopoetic and other types of stem cells found in blood and a variety of tissues. Increased expression of CD133 may be a predictor of decreased prognosis in patients with metastatic cancer. Antibody ANC9C5 recognizes epitope 1 of human CD133 (AC133) present on full length CD133 transfectants, Y79 retinoblastoma and other cell types. Antibody ANC9C5 has been used to image cancer stem cells in a colon carcinoma xenograft.

Product References
  1. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells: Z.-H. Jin, et al.; Mol. Imaging 11, 445 (2012)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.